A federal appeals court yesterday upheld a lower court’s ruling on the claim construction in a patent infringement dispute between the inventor of a vascular stent patent and Endologix (NSDQ:ELGX) acquisition TriVascular Technologies. In February, the U.S. Court of Appeals for the Federal Circuit upheld a Patent Trial & Appeal Board ruling that the patent was not invalid due to obviousness. […]
TriVascular
Seno Medical grabs ex-CeloNova CFO Davis | Personnel Moves August 12, 2016
Seno Medical grabs ex-CeloNova CFO Davis Seno Medical Instuments said this week it tapped former CeloNova BioSciences chief financial officer Eric Davis to take over the CFO role at Seno Medical. Prior to his years at CeloNova, Davis operated as CFO and operating officer at Genesis Networks Enterprises. Seno Medical said that Davis has more than […]
TriVascular loses appeal in patent spat with vascular stent inventor
TriVascular Technologies (NSDQ:TRIV) last Friday lost an appeal in a vascular stent patent spat after a Federal Circuit court upheld a Patent Trial and Appeal Board ruling that found the stent’s patent, held by a separate inventor, was not invalid due to obviousness. The court upheld the ruling on the grounds that TriVascular didn’t demonstrate that the […]
Endologix, TriVascular Technologies close $211m merger
Endologix (NSDQ:ELGX) and TriVascular Technologies (NSDQ:TRIV) said yesterday that they closed their $221 million merger, uniting 2 of the stent graft market’s smaller players. Both companies makes devices for treating abdominal aortic aneurysms; Irvine, Calif.-based Endologix makes 2 lines of stent grants, the Nellix and AFX devices, while Santa Rosa, Calif.-based TriVascular makes the Ovation stent graft. “The completion […]
Endologix, TriVascular clear U.S. regulatory hurdle in $211m merger
Endologix (NSDQ:ELGX) and TriVascular Technologies (NSDQ:TRIV) yesterday said that the waiting period set by U.S. anti-trust laws for their $211 million merger ended early, setting the stage for the deal to close during the 1st quarter next year. The companies said the U.S. Federal Trade Commission and Justice Dept. granted early termination of the waiting period under […]
VIVA 2015 Roundup: Medtronic touts Valiant stent graft, PAD stent-treatment data
Medtronic (NYSE:MDT) this week presented data from 2 studies of its stent systems and announced a new study of its In.Pact Admiral drug-coated balloon. The announcements were made at the VIVA physicians annual conference in Las Vegas, Nev. The Fridley, Minn.-based medical giant presented data from a 2-year clinical trial of its Valiant Captivia thoracic stent graft […]
Endologix, TriVascular Technologies ink $211m merger
Endologix (NSDQ:ELGX) and TriVascular Technologies (NSDQ:TRIV) yesterday said they plan to merge in a cash-and-stock deal worth $211 million. If consummated, the deal would unite 2 of the stent graft market’s smaller players. Both companies makes devices for treating abdominal aortic aneurysms; Irvine, Calif.-based Endologix makes 2 lines of stent grants, the Nellix and AFX devices, while […]
TriVascular Technologies raises $10m, launches study of EVAR in women
Trivascular Technologies (NSDQ:TRIV) said it raised a $10 million funding round and launched a clinical study of endovascular aortic repair in women using its Ovation stent graft. Santa Rosa, Calif.-based TriVascular said in a regulatory filing that it raised $10 million from 5 unnamed investors in a debt-and-warrants offering. The company, which won pre-market approval […]
2014: The year of the medtech IPO | Medtech Wall Street news for the week of December 15, 2014
Year in review: 2014 was the year of the medtech IPO
Click to enlarge
It was, as predicted, the year of the IPO for medical device companies, with 25 filing initial public offerings during 2014, according to a MassDevice.com analysis.
FDA approves TriVascular’s CustomSeal for aortic aneurysms
